Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastro, Lara Maria Lopes de-
dc.contributor.authorSouza, Jacqueline de-
dc.contributor.authorCaldeira, Tamires Guedes-
dc.contributor.authorMapa, Bruna de Carvalho-
dc.contributor.authorSoares, Anna Flávia Matos-
dc.contributor.authorGomes, Bruna Pegorelli-
dc.contributor.authorCroce, Carolina Carvalho Della-
dc.contributor.authorBarcellos, Neila Marcia Silva-
dc.identifier.citationCASTRO, L. M. L. et al. The evaluation of valsartan biopharmaceutics properties. Current Drug Research Reviews, v. 12, p. 1-11, 2020. Disponível em: <>. Acesso em: 10 fev. 2020.pt_BR
dc.description.abstractBackground: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool that uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Method: High performance liquid chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) was observed for both solubility methods. Permeability data reported from literature showed that valsartan is a low permeability drug. Valsartan presented rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are the indicated to define the biopharmaceutics classification by regulatory agencies.pt_BR
dc.subjectBiopharmaceutics classification systempt_BR
dc.titleThe evaluation of valsartan biopharmaceutics properties.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
529,82 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.